On September 30 th, 2016, Emergent BioSolutions provided an update on the status of its 2011 BioThrax® (Anthrax Vaccine Adsorbed) procurement contract and the status of its discussions with the Centers for Disease Control and Prevention (CDC) for a follow-on procurement contract for BioThrax. The company stated that CDC has exercised an option to procure all remaining BioThrax doses, thereby committing to take delivery of the full 44.75 million doses, under the procurement contract announced on October 3 rd, 2011 and due to expire September 30 th, 2016. In concert with this option exercise, CDC has granted a no-cost extension to enable delivery of the remaining doses to be completed by November 30 th, 2016. Visit us today and download our complete research report on EBS for free at: